Vaccine delivery can be achieved by linking antigen to CNT and by inducing antibody response. Use of CNTs can improve
immune response. Tailoring the physical properties of MWNT-based vaccine delivery systems may increase their efficiency
in inducing potent T cell immune responses against challenging infectious or cancer diseases. Tumour-specific, immunebased
therapeutic interventions can be considered as safe and effective approaches for cancer therapy. Exploitation of
nano-vaccinology to intensify the cancer vaccine potency may overcome the need for administration of high vaccine doses
or additional adjuvants and therefore could be a more efficient approach. Carbon nanotubes (CNTs) have shown marked
capabilities in enhancing antigen delivery to antigen presenting cells. However, proper understanding of how altering the
physical properties of CNTs may influence antigen uptake by antigen presenting cells, such as dendritic cells (DCs), has
not been established yet.
Chimeric Antigen Receptors (paper with corresponding power point)Kevin B Hugins
Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...JohnJulie1
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...daranisaha
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients. Drug repurposing sometimes-termed drug repositioning is a strategy of discovery and redeveloping existing drugs for new therapeutic purposes. This novel approach is highly efficient, considerably cuts research and development costs, reduces the drug development timeline, maximizes therapeutic value and consequently increases success rate with minimum risk of failure.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Chimeric Antigen Receptors (paper with corresponding power point)Kevin B Hugins
Gene therapy was first conceptualized to alter debilitating fates of genetic diseases. Gene therapy technology can help introduce new functional DNA to replace mutated genes. The idea first arose in 1972 when Friedmann and Roblin authored a paper, “Gene therapy for human genetic disease?”, demonstrating that exogenous DNA can be taken up by mammalian cells (1). They proposed that the same procedure could be done on humans to correct genetic defects by introducing therapeutic DNA. Currently, genetic modification of T lymphocytes has been the major area of research for treating malignant tumors. This technique seeks to create chimeric antigen receptor (CAR) in T cells by genetically modifying them in vitro and reintroduce them back into blood circulation. The T cells are unique to every patient and the chimeric antigen receptors are unique to the tumor that it is targeting.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...JohnJulie1
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...daranisaha
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients. Drug repurposing sometimes-termed drug repositioning is a strategy of discovery and redeveloping existing drugs for new therapeutic purposes. This novel approach is highly efficient, considerably cuts research and development costs, reduces the drug development timeline, maximizes therapeutic value and consequently increases success rate with minimum risk of failure.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Drug Repurposing: Recent Advancements, Challenges, and Future Therapeutics fo...semualkaira
Cancer is a prime public health burden that accounts for approximately 9.9 million deaths worldwide. Despite recent advances in treatment regimen and huge capital investment in the pharmaceutical sector, there has been little success in improving the chances of survival of cancer patients.
Microbiata
A main player in immunityThe microbiome is an environmental factor in intricate symbiotic relationship with its hosts' immune system, potentially shaping:
anticancer immunity,
autoimmunity, and
transplant responses
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...CrimsonpublishersCancer
Cancer treatments have traditionally entailed system wide toxicity with debilitating side effects for the patient. The demand for targeted therapies is clearly exhibited in the pipeline of large pharmaceuticals where the need to identify delivery vehicles that offer the prospects of more targeted, efficacious treatments with fewer side effects is paramount. Historically a number of technologies have been tried and tested including antibody drug conjugates, nanoparticles, cell surface markers and targeting the tumor microenvironment. Unfortunately, these approaches have often had lackluster results and created alternative toxic profiles, such as immune activation. Interest in an historic technology, cell penetrating peptides (CPPs), has been recently reinvigorated, presenting the opportunity to deliver targeted, biologically active cargoes to cancerous cells for treatment without systemic side effects.
CHI's Targeting Stromal Cells in Cancer and Inflammatory Diseases Conference ...James Prudhomme
This virtual meeting will highlight cutting-edge science and provide insight into recent developments towards therapeutic stromal cell targeting in cancer and chronic inflammatory diseases. View full details and register: https://www.healthtech.com/stroma-conference
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
More Related Content
Similar to carbon-nanotubesbased-intelligent-platform-for-cancer-vaccine-codelivery-nanocarriers-immunotherapy-achievements-challen (1).pdf
Microbiata
A main player in immunityThe microbiome is an environmental factor in intricate symbiotic relationship with its hosts' immune system, potentially shaping:
anticancer immunity,
autoimmunity, and
transplant responses
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...CrimsonpublishersCancer
Cancer treatments have traditionally entailed system wide toxicity with debilitating side effects for the patient. The demand for targeted therapies is clearly exhibited in the pipeline of large pharmaceuticals where the need to identify delivery vehicles that offer the prospects of more targeted, efficacious treatments with fewer side effects is paramount. Historically a number of technologies have been tried and tested including antibody drug conjugates, nanoparticles, cell surface markers and targeting the tumor microenvironment. Unfortunately, these approaches have often had lackluster results and created alternative toxic profiles, such as immune activation. Interest in an historic technology, cell penetrating peptides (CPPs), has been recently reinvigorated, presenting the opportunity to deliver targeted, biologically active cargoes to cancerous cells for treatment without systemic side effects.
CHI's Targeting Stromal Cells in Cancer and Inflammatory Diseases Conference ...James Prudhomme
This virtual meeting will highlight cutting-edge science and provide insight into recent developments towards therapeutic stromal cell targeting in cancer and chronic inflammatory diseases. View full details and register: https://www.healthtech.com/stroma-conference
This ppt file represents a simple overview on what is antibody validation & how to validate an antibody before performing any research.
Used references are also included.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
1. Volume - 1 Issue - 1
Page 1 of 9
Citation: Samuel, O. O., Jerry, I.T. (2023). Measurement Of Background Radiation at Oracle Plastics and Sacks Company in Makurdi, Benue State. Journal of
Theoretical Physics & Mathematics Research. 1(1), 01-07
Volume - 1 Issue - 2
Page 1 of 55
International Journal of
Nursing Care and Research
Loutfy H. Madkour*
Professor of Physical chemistry, Nanoscience and Nanotechnology
Chemistry Department, Faculty of Science, Tanta University, 31527,
Tanta, Egypt.
Carbon Nanotubes—Based Intelligent Platform for Cancer Vac-
cine Co-delivery Nanocarriers Immunotherapy Achievements:
Challenges In vitro and In vivo
Accepted: 2023 Oct 14
Received: 2023 Sep 10
CorrespondingAuthor:Loutfy H. Madkour. Physical
chemistry, Nanoscience and Nanotechnology
Chemistry Department, Faculty of Science, Tanta
University, 31527, Tanta, Egypt.
Abstract
Vaccine delivery can be achieved by linking antigen to CNT and by inducing antibody response. Use of CNTs can improve
immuneresponse.TailoringthephysicalpropertiesofMWNT-basedvaccinedeliverysystemsmayincreasetheirefficiency
in inducing potent T cell immune responses against challenging infectious or cancer diseases. Tumour-specific, immune-
based therapeutic interventions can be considered as safe and effective approaches for cancer therapy. Exploitation of
nano-vaccinology to intensify the cancer vaccine potency may overcome the need for administration of high vaccine doses
or additional adjuvants and therefore could be a more efficient approach. Carbon nanotubes (CNTs) have shown marked
capabilities in enhancing antigen delivery to antigen presenting cells. However, proper understanding of how altering the
physical properties of CNTs may influence antigen uptake by antigen presenting cells, such as dendritic cells (DCs), has
not been established yet.
Althoughanti-cancerimmuno-basedcombinatorialtherapeuticapproacheshaveshownpromisingresults,efficienttumour
eradication demands further intensification of anti-tumour immune response. With the emerging field of nanovaccinology,
multi-walled carbon nanotubes (MWNTs) have manifested prominent potentials as tumour antigen nanocarriers.
Nevertheless, the utilization of MWNTs in co-delivering antigen along with different types of immunoadjuvants to antigen
presenting cells (APCs) has not been investigated yet.
Keywords: Carbon Nanotubes, Vaccine Delivery, Cancer Immunotherapy, Antigen Presenting Cells and Dendritic
Cells.
Published: 2023 Nov 13
Research Article
Ciatation: Madkour, L. H. (2023) Carbon Nanotubes—Based Intelligent Platform for Cancer vaccine Co-delivery Nanocarriers Immunotherapy Achievements:
Challenges In vitro and In vivo. Int J of Nursing Care and Res, 1(2). 1-55.
1. Delivery of vaccines by CNTs
Carbon nanotube (CNT) can be described as carbon sheet(s)
rolled up into a cylinder that is nanometers wide and nano-
meters to micrometers long. Stemming from the observed
capacities of CNTs to enter various types of cells via diver-
sified mechanisms utilizing energy-dependent and/or pas-
sive routes of cell uptake, the use of CNTs for the delivery of
therapeutic agents has drawn increasing interests over the
last decade.
Functionalized CNTs can be used in vaccination procedures.
CNTs were shown to activate cells deriving from the innate
immune system, such as monocytes, macrophages, and
dendritic cells [1]. Microarray profiling of a monocytic cell
line, THP-1, showed that CNTs, both functionalized and non-
functionalized, activate several genes involved in monocyte
response to infection or vaccination, such as nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB), in-
terleukin-1β (IL-1β), IL-6, tumor necrosis factor-α (TNF-α),
among others [2].
CNTs activate the class II Major Immuno-compatibility Com-
plex (MHC) in antigen presenting cells which can, in turn,
promote an antibody-based response. The linkage of either a
bacterial or viral antigen to CNTs allows the maintenance of
antigen conformation integrity, thereby, inducing antibody
response increasing both the specificity and the sensitivity
[3].
It has also been suggested that SWNT conjugated with un-
methylated CpG DNA motifs can be used as an adjuvant in
vaccines. Functionalized CNTs have been demonstrated to
be able to act as carriers for antimicrobial agents, such as the
antifungal amphotericin B. CNTs covalently attached to am-
photericin B reduced the undesired toxicity by about 40% as
compared to the free drug [4].
Moreover, CNTs themselves might have antimicrobial activi-
ty through oxidation of the intracellular antioxidant glutathi-
one, resulting in increased oxidative stress on the bacterial
cells and eventual pathogen death [3].